Search results
Showing 316 to 330 of 725 results for impact reports
This quality standard covers assessing and managing oesophago-gastric cancer in adults. It describes high-quality care in priority areas for improvement.
Evidence-based recommendations on Memokath 051 Ureter stent for ureteric obstruction.
Radiation dose monitoring software for medical imaging with ionising radiation (MIB127)
NICE has developed a medtech innovation briefing (MIB) on radiation dose monitoring software for medical imaging with ionising radiation .
Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma (TA268)
Evidence-based recommendations on ipilimumab (Yervoy) for previously treated advanced melanoma in adults.
Dapagliflozin in combination therapy for treating type 2 diabetes (TA288)
Evidence-based recommendations on dapagliflozin (Forxiga) given with other drugs for treating type 2 diabetes in adults.
Mega Soft Patient Return Electrode for use during monopolar electrosurgery (HTG290)
Evidence-based recommendations on Mega Soft Patient Return Electrode for use during monopolar electrosurgery.
Evidence-based recommendations on SonoVue (sulphur hexafluoride microbubbles) for contrast-enhanced ultrasound imaging of the liver.
This is the user guide for submission of evidence to the National Institute for Health and Care Excellence (NICE) as part of the single technology appraisal and highly specialised technologies evaluations process. It explains what information NICE requires and the format in which it should be presented
NICE has developed a medtech innovation briefing (MIB) on Lifelight First for monitoring vital signs .
UroShield for preventing catheter-associated urinary tract infections (HTG620)
Evidence-based recommendations on UroShield for preventing catheter-associated urinary tract infections.
Evidence summaries: new medicines – Integrated process statement (PMG11)
This integrated process statement has been produced to explain how 'Evidence summaries: new medicines' (ESNMs) are developed. It provides an overview of the key process principles and describes all stages of the development of ESNMs
Developmental follow-up of children and young people born preterm (QS169)
This quality standard covers the developmental follow-up of babies, children and young people under 18 years who were born preterm (before 37+0 weeks of pregnancy). It describes high-quality care in priority areas for improvement.
Psychosis and schizophrenia in adults: prevention and management (CG178)
This guideline covers recognising and managing psychosis and schizophrenia in adults. It aims to improve care through early recognition and treatment, and by focusing on long-term recovery. It also recommends checking for coexisting health problems and providing support for family members and carers.
Evidence-based recommendations on molnupiravir (Lagevrio) for treating mild to moderate COVID-19 in adults who have a positive SARS-CoV-2 test.
User guide for the cost comparison company evidence submission template (PMG32)
This user guide describes how to submit evidence to NICE when a cost-comparison case is made as part of the fast track technology appraisal process. It explains what information NICE requires and the format in which it should be presented